EA201201655A1 - ANTI-TUMOR MEDICINE (OPTIONS) - Google Patents
ANTI-TUMOR MEDICINE (OPTIONS)Info
- Publication number
- EA201201655A1 EA201201655A1 EA201201655A EA201201655A EA201201655A1 EA 201201655 A1 EA201201655 A1 EA 201201655A1 EA 201201655 A EA201201655 A EA 201201655A EA 201201655 A EA201201655 A EA 201201655A EA 201201655 A1 EA201201655 A1 EA 201201655A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- bortezomib
- creation
- isotopes
- minerals
- antitumor agent
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Изобретение относится к области фармацевтической промышленности и медицине и может быть использовано при создании и применении противоопухолевых средств, в частности ингибиторов протеасом на основе бортезомиба. Задачей настоящего изобретения является создание эффективного противоопухолевого средства на базе бортезомиба с расширенными свойствами при использовании. Задача решается за счет того, что противоопухолевое средство содержит бортезомиб, минеральные вещества калий, цинк, изотопы углеродаС, изотопы азотаN. Техническими результатами изобретения являются увеличение лечебного эффекта без увеличения концентрации бортезомиба при лечении злокачественных опухолей за счет использования в противоопухолевом средстве изотоповС,N и минеральных веществ; увеличение времени хранения, в том числе в готовом к применению жидком виде.The invention relates to the pharmaceutical industry and medicine and can be used in the creation and application of anticancer drugs, in particular bortezomiba-based proteasome inhibitors. The present invention is the creation of an effective anticancer agent on the basis of bortezomib with enhanced properties during use. The problem is solved due to the fact that the antitumor agent contains bortezomib, minerals potassium, zinc, carbon isotopes, carbon isotopes of nitrogenN. Technical results of the invention are to increase the therapeutic effect without increasing the concentration of bortezomib in the treatment of malignant tumors due to the use in the antitumor agent isotopes C, N and minerals; increase storage time, including in ready-to-use liquid form.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EA201201655A EA201201655A1 (en) | 2012-12-28 | 2012-12-28 | ANTI-TUMOR MEDICINE (OPTIONS) |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EA201201655A EA201201655A1 (en) | 2012-12-28 | 2012-12-28 | ANTI-TUMOR MEDICINE (OPTIONS) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201201655A1 true EA201201655A1 (en) | 2014-06-30 |
Family
ID=51013753
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201201655A EA201201655A1 (en) | 2012-12-28 | 2012-12-28 | ANTI-TUMOR MEDICINE (OPTIONS) |
Country Status (1)
| Country | Link |
|---|---|
| EA (1) | EA201201655A1 (en) |
-
2012
- 2012-12-28 EA EA201201655A patent/EA201201655A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201590941A1 (en) | GLETAMINASE HETEROCYCLIC INHIBITORS | |
| MX2016016744A (en) | Ezh2 inhibitors for treating lymphoma. | |
| UY35082A (en) | OXYGEN CARRIER SUBSTANCE BASED ON HEMOGLOBIN CONTAINING A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER AND THE PREVENTION OF CANCER RECURRENCE | |
| MX2017015896A (en) | Anticancer agent. | |
| PH12016501554A1 (en) | Anticancer adjuvant composition containing rip3 expression promoter as active ingredient, method for screening for anticancer adjuvant enhancing sensitivity of anticancer drug by promoting rip3 expression, and method for monitoring sensitivity of anticancer drug | |
| EA201201654A1 (en) | ANTI-TUMOR MEDICINE (OPTIONS) | |
| EA201201655A1 (en) | ANTI-TUMOR MEDICINE (OPTIONS) | |
| EA201201589A1 (en) | ANTI-TUMOR MEDICINE (OPTIONS) | |
| EA201201586A1 (en) | ANTI-TUMOR MEDICINE (OPTIONS) | |
| EA201201584A1 (en) | ANTI-TUMOR MEDICINE (OPTIONS) | |
| EA201201616A1 (en) | ANTI-TUMOR MEDICINE (OPTIONS) | |
| EA201201588A1 (en) | ANTI-TUMOR MEDICINE (OPTIONS) | |
| EA201201587A1 (en) | ANTI-TUMOR MEDICINE (OPTIONS) | |
| EA201201590A1 (en) | ANTI-TUMOR MEDICINE (OPTIONS) | |
| EA201201585A1 (en) | ANTI-TUMOR MEDICINE (OPTIONS) | |
| NZ725067A (en) | Anti-tumor agent containing anti-tumor platinum complex, and anti-tumor effect enhancer | |
| RU2014146031A (en) | Pharmaceutical gel based on doxorubicin and organosilicon niosomes-niosomes for the treatment of skin cancer | |
| EA201992500A3 (en) | Salts and Drugs of 1-Methyl-D-Tryptophan | |
| EA201300373A1 (en) | ANTIOXIDANT PHARMACEUTICAL COMPOSITION (OPTIONS) | |
| EA201300370A1 (en) | ANTIOXIDANT PHARMACEUTICAL COMPOSITION (OPTIONS) | |
| EA201200464A1 (en) | SOLID MEDICINE FORM WITH A FUNNY RELIEF, LOCAL ENVIRONMENT AND ANTI-INFLAMMATORY ACTION (OPTIONS) | |
| EA201300371A1 (en) | ANTIOXIDANT PHARMACEUTICAL COMPOSITION (OPTIONS) | |
| EA201200462A1 (en) | SOLID MEDICINE FORM WITH A FUNNY RELIEF, LOCAL ENVIRONMENT AND ANTI-INFLAMMATORY ACTION (OPTIONS) | |
| EA201200463A1 (en) | SOLID MEDICINE FORM WITH A FUNNY RELIEF, LOCAL ENVIRONMENT AND ANTI-INFLAMMATORY ACTION (OPTIONS) | |
| EA201200450A1 (en) | SOLID MEDICINE FORM WITH A FUNNY RELIEF, LOCAL ENVIRONMENT AND ANTI-INFLAMMATORY ACTION (OPTIONS) |